Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma.
Intern Med
; 61(21): 3157-3164, 2022.
Article
in En
| MEDLINE
| ID: mdl-36328582
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Hepatocellular
/
Liver Neoplasms
Type of study:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Intern Med
Journal subject:
MEDICINA INTERNA
Year:
2022
Document type:
Article
Affiliation country: